Angesichts des Drucks der Trump-Regierung hat der Schweizer Pharmariese Roche seine seit langem bestehenden globalen ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in ...

Swiss pharmaceutical giant Roche is cutting its global diversity workforce targets, aligning with recent U.S. legal changes ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...